Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areas
Angela Michelucci(University of Pisa), M. Romanelli(University of Pisa), Imma Savarese(University of Florence), Elisabetta Rosi(University of Florence), Salvatore Panduri(University of Pisa), Michela Magnano(Ospedale Santa Chiara), E Lorenzoni(IMT School for Advanced Studies Lucca), Emanuele Trovato(University of Siena), Martina Dragotto(University of Florence), Federica Ricceri(Ospedale San Donato), Leonardo Pescitelli(University of Florence), Antonella Di Cesare(University of Florence), Alessandra Cartocci(University of Siena), Flavia Manzo Margiotta(Scuola Superiore Sant'Anna), Pietro Rubegni(University of Siena), Gionata Buggiani(Ospedale San Giuseppe), Francesca Prignano(University of Florence), Nicola Milanesi(Ospedale del Ceppo), Susanna Rossari(University of Florence), E. Calpalbo(University of Siena), B. Simoni(IMT School for Advanced Studies Lucca)
Cited by 5
Related Papers
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
|Autoimmunity Reviews|2015|198
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*
|British Journal of Dermatology|2020|175
The Spectrum of Spitz Nevi
|Archives of Dermatology|2005|173
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
|Journal of Allergy and Clinical Immunology|2020|160
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
|Journal of the European Academy of Dermatology and Venereology|2024|126